초록 ▼

In accordance with the present invention, a system controller and method for monitoring and controlling a plurality of generator sets are provided. Each generator set generates electrical power and includes a generator communications link for connecting a generator set to a network. A user interface

In accordance with the present invention, a system controller and method for monitoring and controlling a plurality of generator sets are provided. Each generator set generates electrical power and includes a generator communications link for connecting a generator set to a network. A user interface allows a user to select a generator set and set values for various predetermined operating parameters of the selected generator sets. Thereafter, a communications link connectable to the network transmits the user set values of the predetermined operating parameters to the selected generator set.

대표청구항 ▼

In accordance with the present invention, a system controller and method for monitoring and controlling a plurality of generator sets are provided. Each generator set generates electrical power and includes a generator communications link for connecting a generator set to a network. A user interface

In accordance with the present invention, a system controller and method for monitoring and controlling a plurality of generator sets are provided. Each generator set generates electrical power and includes a generator communications link for connecting a generator set to a network. A user interface allows a user to select a generator set and set values for various predetermined operating parameters of the selected generator sets. Thereafter, a communications link connectable to the network transmits the user set values of the predetermined operating parameters to the selected generator set. erocyclic, and heterocyclicC1-4alkyl; or R4and R5together with the nitrogen to which they are attached form a 5 to 7 member ring which optionally comprises an additional heteroatom selected from oxygen, nitrogen and sulfur; Y is independently selected from the group consisting of hydrogen, halogen, nitro, cyano, halosubstituted C1-10alkyl, C1-10alkyl, C2-10alkenyl, C1-10alkoxy, halosubstituted C1-10alkoxy, azide, (CR8R8)q S(O)tR4,hydroxy, hydroxyC1-4alkyl, aryl, aryl C1-4alkyl, aryloxy, arylC1-4alkyloxy, heteroaryl, heteroarylalkyl, heteroaryl C1-4alkyloxy, heterocyclic, heterocyclic C1-4alkyl, aryl C2-10alkenyl, heteroaryl C2-10alkenyl, heterocyclic C2-10alkenyl, (CR8R8)q NR4R5,C2-10alkenyl C(O)NR4R5,(CR8R8)q C(O)NR4R5,(CR8R8)q C(O)NR4R10,S(O)3H; S(O)3R8,(CR8R8)q C(O)R11,C2-10alkenyl C(O)R11,C2-10alkenyl C(O)OR11,C(O)R11,(CR8R8)q C(O)OR12,(CR8R8)q OC(O)R11,(CR8R8)q NR4C(O)R11,(CR8R8)q NHS(O)2Rd,and (CR8R8)q S(O)2NR4R5; or two Y moieties together form O--(CH2)sO-- or a 5 to 6 membered unsaturated ring; n is an integer having a value of 1 to 5; m is an integer having a value of 1 to 4; R8is hydrogen or C1-4alkyl; R10is C1-10alkyl C(O)2R8; R11is selected from the group consisting of hydrogen, C1-4alkyl, optionally substituted aryl, optionally substituted aryl C1-4alkyl, optionally substituted heteroaryl, optionally substituted heteroarylC1-4alkyl, optionally substituted heterocyclic, and optionally substituted heterocyclicC1-4alkyl; R12is selected from the group consisting of hydrogen, C1-10alkyl, optionally substituted aryl and optionally substituted arylalkyl; and R17is selected from the group consisting of C1-4alkyl, aryl, arylalkyl, heteroaryl, heteroarylC1-4alkyl, heterocyclic, and heterocyclicC1-4alkyl, wherein the aryl, heteroaryl and heterocyclic rings are all optionally substituted. 2. A compound according to claim 1 selected from the group consisting of: N-(4-Cyano-2-hydroxyphenyl)-N'-(2-bromophenyl)-sulfamide; N-(4-Cyano-2-hydroxyphenyl)-N'-(2-chlorophenyl)-sulfamide; N-(4-Cyano-2-hydroxyphenyl)-N'-(2,3-dichlorophenyl)-sulfamide; N-(4-Nitro-2-hydroxyphenyl)-N'-(2-bromophenyl)-sulfamide; and N-(4-Chloro-2-hydroxyphenyl)-N'-(2-bromophenyl)-sulfamide. 3. A pharmaceutical composition comprising an effective amount of a compound according to claim 1, and a pharmaceutically acceptable carrier or diluent. 4. A method of treating a chemokine mediated disease state, wherein the chemokine binds to an IL-8α or β receptor in a mammal, which comprises administering to said mammal an effective amount of a compound of the formula according to claim 1. 5. The method according to claim 4 wherein the mammal is afflicted with a chemokine mediated disease selected from the group consisting of psoriasis, atopic dermatitis, osteo arthritis, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, adult respiratory distress syndrome, inflammatory bowel disease, Crohn's disease, ulcerative colitis, stroke, septic shock, multiple sclerosis, endotoxic shock, gram negative sepsis, toxic shock syndrome, cardi ac and renal reperfusion injury, glomerulonephritis, thrombosis, graft vs. host reaction, Alzheimer's disease, allograft rejections, malaria, restenosis, angiogenesis, atherosclerosis, osteoporosis, gingivitis and undesired hematopoietic stem cells release and diseases caused by respiratory viruses, herpes viruses, and hepatitis viruses, meningitis, cystic fibrosis, pre-term labor, cough, pruritus, multi-organ dysfunction, trauma, strains, sprains, contusions, psoriatic arthritis, herpes, encephalitis, CNS vasculitis, traumatic brain injury, CNS tumors, subarachnoid hemorrhage, post surgical trauma, interstitial pneumonitis, hypersensitivity, crystal induced arthritis, acute and chronic pancreatitis, acute alcoholic hepatitis, necrotizing enterocolitis, chronic sinusitis, uveitis, polymyositis, vasculitis, acne, gastric and duodenal ulcers, celiac disease, esophagitis, glossitis, airflow obstruction, airway hyperresponsiveness, bronchiolitis obliterans organizing pneumonia, bronchiectasis, bronchiolitis, bronchiolitis obliterans, chronic bronchitis, cor pulmonae, dyspnea, emphysema, hypercapnea, hyperinflation, hypoxemia, hyperoxia-induced inflammations, hypoxia, surgical lung volume reduction, pulmonary fibrosis, pulmonary hypertension, right ventricular hypertropy, sarcoidosis, small airway disease, ventilation-perfusion mismatching, wheeze, colds and lupus.